{
    "hands_on_practices": [
        {
            "introduction": "Pain is not a monolithic sensation; the sharp sting of a paper cut feels very different from the dull ache of a bruise. This exercise explores the fundamental reason for this difference: the two major types of nerve fibers that carry pain signals to the brain. By analyzing distinct pain scenarios , you will learn to connect the characteristics of a painful experience to the specific class of nociceptor and the conduction velocity of its afferent fiber.",
            "id": "1753990",
            "problem": "A sensory physiologist is conducting an experiment to differentiate the neural pathways of pain perception. Two distinct, localized stimuli are applied to a subject's skin on separate occasions.\n\nStimulus 1 consists of a brief, sharp prick from a sterile, fine-tipped mechanical probe. The subject reports an immediate, sharp, and easily localized pricking sensation. This is often referred to as \"first pain\".\n\nStimulus 2 involves the application of a small drop of a solution containing a mild chemical irritant. The subject reports a sensation that develops more slowly, feels dull and burning, and is poorly localized. This is characteristic of \"second pain\".\n\nBased on these observations, identify the primary class of nociceptors and the predominant type of afferent nerve fiber that transduce and transmit the initial sensory signal for each stimulus.\n\nA. Stimulus 1: Mechanical nociceptors via C fibers; Stimulus 2: Polymodal nociceptors via A-delta (Aδ) fibers.\n\nB. Stimulus 1: Mechanical nociceptors via A-delta (Aδ) fibers; Stimulus 2: Polymodal nociceptors via C fibers.\n\nC. Stimulus 1: Polymodal nociceptors via A-delta (Aδ) fibers; Stimulus 2: Mechanical nociceptors via C fibers.\n\nD. Stimulus 1: silent nociceptors via C fibers; Stimulus 2: Thermal nociceptors via A-delta (Aδ) fibers.\n\nE. Stimulus 1: Thermal nociceptors via A-delta (Aδ) fibers; Stimulus 2: Mechanical nociceptors via C fibers.",
            "solution": "We first classify the sensations by their temporal profile and quality, which are governed by nociceptor class and afferent fiber type.\n\nFor Stimulus 1 (brief, sharp, well-localized “first pain”): The key features are rapid onset and precise localization. The physiological principle is that faster conduction arises from myelination and larger axon diameter. Thinly myelinated A-delta fibers conduct faster than unmyelinated C fibers, producing the early “first pain.” The transducing receptors for a brief, punctate mechanical probe are mechanical (often mechanothermal) nociceptors that are activated by high-threshold mechanical stimuli. Therefore, Stimulus 1 is mediated by mechanical nociceptors carried predominantly by A-delta fibers.\n\nFor Stimulus 2 (slowly developing, dull, burning, poorly localized “second pain”): The temporal delay and diffuse, burning quality indicate the slow-conducting, unmyelinated C fibers. The transducing receptors for a mild chemical irritant are typically polymodal nociceptors, which respond to chemical, thermal, and mechanical stimuli and predominantly project via C fibers, producing the delayed “second pain.” Although “silent” nociceptors can be recruited after inflammation, the canonical mediator of a mild chemical irritant–evoked dull burn is the polymodal C-fiber nociceptor.\n\nMatching these to the options:\n- Stimulus 1: mechanical nociceptors via A-delta fibers.\n- Stimulus 2: polymodal nociceptors via C fibers.\n\nThis corresponds to option B.",
            "answer": "$$\\boxed{B}$$"
        },
        {
            "introduction": "The signals relayed by nociceptive fibers are trains of action potentials, the universal currency of the nervous system. The precise shape and timing of these electrical events are critical for encoding the intensity and duration of a stimulus. This problem  challenges you to predict how a specific neurotoxin, by blocking key ion channels, alters the fundamental properties of the action potential, thereby changing how a nociceptor responds to and communicates a painful stimulus.",
            "id": "1754022",
            "problem": "A neurophysiologist is studying a specific type of nociceptive (pain-sensing) neuron. In its normal state, when subjected to a sustained, constant, suprathreshold depolarizing current, this neuron fires a regular train of action potentials. The rapid depolarization phase of each action potential is driven by the influx of sodium ions through voltage-gated sodium channels ($Na_v$), while the subsequent repolarization phase is primarily caused by the efflux of potassium ions through delayed-rectifier voltage-gated potassium channels ($K_v$).\n\nA novel peptide, NociToxin-K, isolated from tarantula venom, is found to be a highly specific and potent blocker of these delayed-rectifier $K_v$ channels without affecting $Na_v$ channels or potassium leak channels that set the resting membrane potential. The neurophysiologist applies NociToxin-K to the neuron and then applies the same sustained, constant, suprathreshold depolarizing current as before.\n\nWhich of the following descriptions most accurately predicts the primary changes to the action potentials and the firing pattern of the neuron after the application of NociToxin-K?\n\nA. The resting membrane potential will become significantly more positive (depolarized), leading to a higher frequency of spontaneous action potentials.\n\nB. The duration of each action potential will increase, and the maximum firing frequency will decrease.\n\nC. The duration of each action potential will decrease, and the maximum firing frequency will increase.\n\nD. The peak amplitude of the action potentials will be significantly reduced, but the firing frequency will remain unchanged.\n\nE. The neuron will fail to produce any action potentials because repolarization is completely blocked.",
            "solution": "We model the membrane using a current-balance equation of the Hodgkin–Huxley form:\n$$\nC_{m}\\frac{dV}{dt} = I_{\\text{inj}} - I_{\\text{Na}} - I_{\\text{K,DR}} - I_{\\text{leak}},\n$$\nwith\n$$\nI_{\\text{Na}} = g_{\\text{Na}} m^{3}h\\,(V - E_{\\text{Na}}), \\quad\nI_{\\text{K,DR}} = g_{\\text{K}} n^{4}\\,(V - E_{\\text{K}}), \\quad\nI_{\\text{leak}} = g_{\\text{L}}(V - E_{\\text{L}}).\n$$\nNociToxin-K specifically blocks delayed-rectifier potassium channels, so its primary effect is $g_{\\text{K}} \\to 0$ while leaving $g_{\\text{Na}}$ and $g_{\\text{L}}$ unchanged.\n\nResting potential: At rest with no injected current, $I_{\\text{inj}}=0$ and the gating variables satisfy $m \\approx 0$, $h \\approx 1$, $n \\approx 0$, so $I_{\\text{Na}} \\approx 0$ and $I_{\\text{K,DR}} \\approx 0$ even before the block. The steady state is therefore determined by $I_{\\text{leak}}$:\n$$\n0 = - I_{\\text{leak}} \\implies g_{\\text{L}}(V - E_{\\text{L}})=0 \\implies V \\approx E_{\\text{L}}.\n$$\nBecause $g_{\\text{L}}$ and $E_{\\text{L}}$ are unchanged, the resting membrane potential is not significantly altered. This rules out the claim in option A.\n\nAction potential upstroke and peak: The rapid depolarization is driven by $I_{\\text{Na}}$, which is unchanged because $g_{\\text{Na}}$ is unaffected. The peak of the action potential approaches $E_{\\text{Na}}$ (set by sodium equilibrium), so the peak amplitude is not expected to be significantly reduced by removing $g_{\\text{K}}$. This contradicts D.\n\nRepolarization and duration: The falling phase is governed by the outward currents present during the spike. With $g_{\\text{K}} \\to 0$, the major outward current $I_{\\text{K,DR}}$ is removed. Repolarization must then proceed via sodium channel inactivation (reducing $I_{\\text{Na}}$) and the small leak current. The effective conductance during repolarization decreases, increasing the membrane time constant\n$$\n\\tau_{\\text{fall}} \\sim \\frac{C_{m}}{g_{\\text{out,eff}}},\n$$\nwhere $g_{\\text{out,eff}}$ is dominated by $g_{\\text{K}}$ in control and by $g_{\\text{L}}$ after the block. Since $g_{\\text{out,eff}}$ decreases when $g_{\\text{K}}$ is blocked, $\\tau_{\\text{fall}}$ increases and the action potential broadens. Thus, the duration of each action potential increases. This contradicts C and supports B.\n\nRefractoriness and firing frequency: Recovery from inactivation of sodium channels ($h$ returning toward its resting value) is voltage dependent and accelerates at more hyperpolarized potentials. With reduced repolarization and diminished afterhyperpolarization, the membrane remains more depolarized for longer, slowing recovery of $h$ and lengthening the refractory period. A simple upper bound for repetitive firing is\n$$\nf_{\\max} \\approx \\frac{1}{T_{\\text{AP}} + T_{\\text{refr}}},\n$$\nwhere $T_{\\text{AP}}$ is action potential duration and $T_{\\text{refr}}$ the refractory interval. Both increase when $g_{\\text{K}}$ is blocked, implying a decrease in $f_{\\max}$. Therefore, the maximum firing frequency decreases. This supports B.\n\nFailure to repolarize completely is not expected because $I_{\\text{Na}}$ inactivates and $I_{\\text{leak}}$ remains; repolarization is slowed, not abolished, so action potentials can still occur under sustained depolarization. Thus, E is incorrect.\n\nCollectively, the primary changes are an increased action potential duration and a decreased maximum firing frequency, which matches option B.",
            "answer": "$$\\boxed{B}$$"
        },
        {
            "introduction": "The experience of pain is not simply a direct transmission of a signal from the periphery to the brain; it is profoundly shaped by our brain's own descending modulatory systems. This powerful top-down control can be influenced by our expectations, emotions, and the context of the injury. This practice problem  uses a simplified mathematical model to quantify how psychological factors, like the placebo effect, can interact with pharmacological treatments to alter perceived pain, offering insight into the complex integration that occurs within the central nervous system.",
            "id": "1754027",
            "problem": "A team of neurophysiologists is investigating the mechanisms of pain perception using a simplified linear model for descending pain modulation. In this model, the final perceived pain ($P$) is the result of an initial ascending nociceptive signal ($N_0$) being attenuated by the central nervous system. The baseline perceived pain in a conscious subject with minimal expectation is $P_{control}$, which incorporates a tonic (constant) level of descending inhibition. Additional pain relief can be achieved through two primary mechanisms: an expectation-driven (placebo) effect and a pharmacological effect from an analgesic drug.\n\nThe total modulation, $M_{total}$, which reduces the pain from the baseline level, is the sum of the placebo modulation, $M_p$, and the drug modulation, $M_d$.\n$P = P_{control} - M_{total} = P_{control} - (M_p + M_d)$\n\nThe placebo modulation is assumed to be directly proportional to a quantifiable 'expectation score' ($E$), which is assessed on a 0-10 scale: $M_p = kE$, where $k$ is a constant 'placebo coupling factor'. The drug modulation, $M_d$, is a constant value $\\delta$ when the drug is administered, and zero otherwise.\n\nIn a clinical trial, a standardized noxious thermal stimulus is applied. The perceived pain is measured on a 0-100 Visual Analog Scale (VAS).\nThe control group (no treatment) reports an average pain score of $P_{control} = 75.0$.\n\nIn the first experimental arm, subjects are given an inert pill but are told it is a potent analgesic, inducing a high expectation score of $E_{high} = 8.0$. This placebo group reports an average pain score of $P_{placebo, high} = 61.0$.\n\nIn the second experimental arm, subjects are given a new analgesic drug and are given the same high-expectation instructions, resulting in the same expectation score $E_{high} = 8.0$. This group reports an average pain score of $P_{drug, high} = 43.0$.\n\nA third experimental arm is now proposed. Subjects will receive the same analgesic drug, but will be given neutral instructions, resulting in a low expectation score of $E_{low} = 2.5$.\n\nAssuming the linear model of pain modulation is accurate, predict the average pain score ($P_{drug, low}$) for this new, low-expectation drug group. Express your answer on the 0-100 pain scale, rounded to three significant figures.",
            "solution": "We use the linear modulation model $P = P_{control} - (M_{p} + M_{d})$ with $M_{p} = kE$ and $M_{d} = \\delta$ when the drug is given, and $M_{d} = 0$ otherwise.\n\nFrom the high-expectation placebo arm (no drug), the perceived pain is\n$$\nP_{placebo,high} = P_{control} - k E_{high}.\n$$\nSolving for $k$ gives\n$$\nk = \\frac{P_{control} - P_{placebo,high}}{E_{high}}.\n$$\nSubstituting the given values $P_{control} = 75.0$, $P_{placebo,high} = 61.0$, and $E_{high} = 8.0$,\n$$\nk = \\frac{75.0 - 61.0}{8.0} = \\frac{14.0}{8.0} = 1.75.\n$$\n\nFrom the high-expectation drug arm, the perceived pain is\n$$\nP_{drug,high} = P_{control} - (k E_{high} + \\delta).\n$$\nSolving for $\\delta$ yields\n$$\n\\delta = P_{control} - P_{drug,high} - k E_{high}.\n$$\nSubstituting $P_{control} = 75.0$, $P_{drug,high} = 43.0$, $k = 1.75$, and $E_{high} = 8.0$,\n$$\n\\delta = 75.0 - 43.0 - 1.75 \\times 8.0 = 32.0 - 14.0 = 18.0.\n$$\n\nFor the proposed low-expectation drug arm with $E_{low} = 2.5$, the predicted pain is\n$$\nP_{drug,low} = P_{control} - (k E_{low} + \\delta).\n$$\nSubstituting $P_{control} = 75.0$, $k = 1.75$, $E_{low} = 2.5$, and $\\delta = 18.0$,\n$$\nP_{drug,low} = 75.0 - (1.75 \\times 2.5 + 18.0) = 75.0 - (4.375 + 18.0) = 75.0 - 22.375 = 52.625.\n$$\nRounded to three significant figures, this is $52.6$ on the 0-100 VAS scale.",
            "answer": "$$\\boxed{52.6}$$"
        }
    ]
}